How a global CRO used GPI Pulse™ to streamline feasibility workflows and strengthen sponsor recommendations

Feasibility teams at global CROs are under increasing pressure to deliver faster answers—often across multiple therapy…

Feasibility teams at global CROs are under increasing pressure to deliver faster answers—often across multiple therapy…

Leveraging our data and analytics platform and proprietary methodology we provided a large pharmaceutical company with net price forecasting and launch optimisation for an IO asset.

GPI and Model N address key challenges for pricing and launch excellence for a global pharmaceutical company.

GPI consulting identified drivers to mitigate global price and revenue erosion based on tender strategy, market context and competitor landscape within hemophilia.

Using our award-winning, robust market access data we identified the relative clinical positioning in core EU markets while defining realistic value-based price estimations within the ultra-orphan space.

GPI supported a large biopharmaceutical company in forecasting their early-stage assets.

GPI developed price and product allocation strategy